Association of haptoglobin genotype and common cardiovascular risk factors with the amount of iron in atherosclerotic carotid plaques

Atherosclerosis

Volumn 216, Issue 1, 2011, Pages 131-138

  Lioupis, Christos ^a   Barbatis, Calypso ^a   Drougou, Aggeliki ^a   Koliaraki, Vasiliki ^b   Mamalaki, Avgi ^b   Klonaris, Christos ^c   Georgopoulos, Sotirios ^c   Andrikopoulos, Vasilios ^a   Bastounis, Elias ^c  

^a RED CROSS HOSPITAL   (Greece)

^b HELLENIC PASTEUR INSTITUTE   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

Author keywords

Carotid plaques; Haptoglobin genotype; Homocysteine; Intraplaque hemorrhage; Iron

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; HAPTOGLOBIN; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRON;

AGED; ARTICLE; CARDIOVASCULAR RISK; CAROTID ARTERY OBSTRUCTION; CAROTID ATHEROSCLEROSIS; CAROTID ENDARTERECTOMY; DIABETES MELLITUS; FEMALE; GENOTYPE; HISTOLOGY; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEX DIFFERENCE;

AGED; CARDIOVASCULAR DISEASES; CAROTID STENOSIS; DIABETES MELLITUS; ENDARTERECTOMY, CAROTID; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GREECE; HAPTOGLOBINS; HEMOSIDERIN; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; HYPOGLYCEMIC AGENTS; IRON; LINEAR MODELS; MALE; MIDDLE AGED; OXIDATIVE STRESS; PHENOTYPE; PLAQUE, ATHEROSCLEROTIC; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX FACTORS; STAINING AND LABELING;

EID: 79955535612     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.01.028     Document Type: Article

References (43)

1. Kockx M.M., Cromheeke K.M., Knaapen M.W., et al. Phagocytosis and macrophage activation associated with hemorrhagic microvessels in human atherosclerosis. Arterioscler Thromb Vasc Biol 2003, 23:440-446.
2. Virmani R., Kolodgie F.D., Burke A.P., et al. Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol 2005, 25:2054-2061.
3. Levy A.P., Moreno P.R. Intraplaque hemorrhage. Curr Mol Med 2006, 6:479-488.
4. Moreno P.R., Fuster V. New aspects in the pathogenesis of diabetic atherothrombosis. J Am Coll Cardiol 2004, 44:2293-2300.
5. McCarthy M.J., Loftus I.M., Thompson M.M., et al. Angiogenesis and the atherosclerotic carotid plaque: an association between symptomatology and plaque morphology. J Vasc Surg 1999, 30:261-268.
6. Virmani R., Narula J., Farb A. When neoangiogenesis ricochets. Am Heart J 1998, 136:937-939.
7. Lonn E., Yusuf S., Arnold M.J., et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006, 354:1567-1577.
8. Moreno P.R., Purushothaman K.R., Purushothaman M., et al. Haptoglobin genotype is a major determinant of the amount of iron in the human atherosclerotic plaque. J Am Coll Cardiol 2008, 52:1049-1051.
9. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med 1991, 325:445-453.
10. Moneta G.L., Edwards J.M., Chitwood R.W., et al. Correlation of North American Symptomatic Carotid Endarterectomy Trial (NASCET) angiographic definition of 70-99% internal carotid artery stenosis with duplex scanning. J Vasc Surg 1993, 152-157(17):157-159. [Discussion].
11. Biasi G.M., Froio A., Diethrich E.B., et al. Carotid plaque echolucency increases the risk of stroke in carotid stenting: the Imaging in Carotid Angioplasty and Risk of Stroke (ICAROS) study. Circulation 2004, 110:756-762.
12. Triposkiadis F., Sitafidis G., Kostoulas J., et al. Carotid plaque composition in stable and unstable coronary artery disease. Am Heart J 2005, 150:782-789.
13. Stary H.C. Natural history and histological classification of atherosclerotic lesions: an update. Arterioscler Thromb Vasc Biol 2000, 20:1177-1178.
14. Frank M., Evan L.O., Szafranek B., Levy T., Ricklis N., Levy R.A. Structure-function analysis of the anti-oxidant properties of haptoglobin. Blood 2001, 98:3693-3698.
15. Asleh R., Marsh S., Shilkrut M., et al. Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. Circ Res 2003, 92:1193-1200.
16. Bowman B.H., Kurosky A. Haptoglobin: the evolutionary product of duplication, unequal crossing over, and point mutation. Adv Hum Genet 1982, 189-261(12):184-453.
17. Hochberg I., Roguin A., Nikolsky E., Chanderashekhar P.V., Cohen S., Levy A.P. Haptoglobin phenotype and coronary artery collaterals in diabetic patients. Atherosclerosis 2002, 161:441-446.
18. Wassell J., Keevil B. A new method for haptoglobin phenotyping. Ann Clin Biochem 1999, 36(Pt 5):609-612.
19. Koch W., Latz W., Eichinger M., et al. Genotyping of the common haptoglobin Hp 1/2 polymorphism based on PCR. Clin Chem 2002, 48:1377-1382.
20. Levy A.P., Purushothaman K.R., Levy N.S., et al. Downregulation of the hemoglobin scavenger receptor in individuals with diabetes and the Hp 2-2 genotype: implications for the response to intraplaque hemorrhage and plaque vulnerability. Circ Res 2007, 101:106-110.
21. Kalet-Litman S., Moreno P.R., Levy A.P. The haptoglobin 2-2 genotype is associated with increased redox active hemoglobin derived iron in the atherosclerotic plaque. Atherosclerosis 2009.
22. Rother R.P., Bell L., Hillmen P., Gladwin M.T. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA 2005, 293:1653-1662.
23. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820.
24. Du X., Matsumura T., Edelstein D., et al. Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest 2003, 112:1049-1057.
25. Moreno P.R., Purushothaman K.R., Fuster V., O'Connor W.N. Intimomedial interface damage and adventitial inflammation is increased beneath disrupted atherosclerosis in the aorta: implications for plaque vulnerability. Circulation 2002, 105:2504-2511.
26. Pasterkamp G., Schoneveld A.H., Hijnen D.J., et al. Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteases 1, 2 and 9 in the human coronary artery. Atherosclerosis 2000, 150:245-253.
27. Miller Y.I., Altamentova S.M., Shaklai N. Oxidation of low-density lipoprotein by hemoglobin stems from a heme-initiated globin radical: antioxidant role of haptoglobin. Biochemistry 1997, 36:12189-12198.
28. Bamm V.V., Tsemakhovich V.A., Shaklai M., Shaklai N. Haptoglobin phenotypes differ in their ability to inhibit heme transfer from hemoglobin to LDL. Biochemistry 2004, 43:3899-3906.
29. Melamed-Frank M., Lache O., Enav B.I., et al. Structure-function analysis of the antioxidant properties of haptoglobin. Blood 2001, 98:3693-3698.
30. Asleh R., Miller-Lotan R., Aviram M., et al. Haptoglobin genotype is a regulator of reverse cholesterol transport in diabetes in vitro and in vivo. Circ Res 2006, 99:1419-1425.
31. Jeziorska M., Woolley D.E. Local neovascularization and cellular composition within vulnerable regions of atherosclerotic plaques of human carotid arteries. J Pathol 1999, 188:189-196.
32. Levy A.P., Hochberg I., Jablonski K., et al. Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: the strong heart study. J Am Coll Cardiol 2002, 40:1984-1990.
33. Roguin A., Koch W., Kastrati A., et al. Haptoglobin genotype is predictive of major adverse cardiac events in the 1-year period after percutaneous transluminal coronary angioplasty in individuals with diabetes. Diabetes Care 2003, 26:2628-2631.
34. Milman U., Blum S., Shapira C., et al. Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a prospective double-blinded clinical trial. Arterioscler Thromb Vasc Biol 2008, 28:341-347.
35. Costacou T., Ferrell R.E., Orchard T.J. Haptoglobin genotype: a determinant of cardiovascular complication risk in type 1 diabetes. Diabetes 2008, 57:1702-1706.
36. Suleiman M., Aronson D., Asleh R., et al. Haptoglobin polymorphism predicts 30-day mortality and heart failure in patients with diabetes and acute myocardial infarction. Diabetes 2005, 54:2802-2806.
37. Levy A.P., Gerstein H.C., Miller-Lotan R., et al. The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes. Diabetes Care 2004, 27:2767.
38. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002, 288:2015-2022.
39. Held C., Sumner G., Sheridan P., et al. Correlations between plasma homocysteine and folate concentrations and carotid atherosclerosis in high-risk individuals: baseline data from the Homocysteine and Atherosclerosis Reduction Trial (HART). Vasc Med 2008, 13:245-253.
40. Carmody B.J., Arora S., Avena R., et al. Folic acid inhibits homocysteine-induced proliferation of human arterial smooth muscle cells. J Vasc Surg 1999, 30:1121-1128.
41. Undas A., Brozek J., Szczeklik A. Homocysteine and thrombosis: from basic science to clinical evidence. Thromb Haemost 2005, 94:907-915.
42. Eldibany M.M., Caprini J.A. Hyperhomocysteinemia and thrombosis: an overview. Arch Pathol Lab Med 2007, 131:872-884.
43. Nygard O., Refsum H., Ueland P.M., Vollset S.E. Major lifestyle determinants of plasma total homocysteine distribution: the Hordaland homocysteine study. Am J Clin Nutr 1998, 67:263-270.